AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO

Their core work

Città della Salute e della Scienza di Torino is one of Italy's largest university hospital complexes, serving as both a clinical care provider and a research hub in Turin. In H2020, they contribute clinical data, patient cohorts, and medical expertise to large-scale European studies focused on cancer screening optimization and liver disease treatment. Their work bridges clinical practice and health research — they provide real-world patient populations and clinical validation for risk-stratified screening models, AI-driven diagnostics, and combinatorial drug therapies. They are a data-rich clinical partner, not a technology developer, making them essential for projects that need hospital-grade evidence and patient access.

What they specialise in

How they've shifted over time

Their early H2020 work (2015–2018) centered on traditional clinical research: liver cirrhosis drug combinations, breast cancer screening with genetic risk scores, and diabetes progression studies. From 2019 onward, a clear digital shift emerged — they joined DeepHealth for AI-powered diagnostics and moved into data-driven, risk-stratified cervical cancer screening with predictive and health-economic modelling (RISCC). The progression shows a hospital evolving from purely clinical trial participation toward digitally-enhanced, precision screening programs.

Moving toward AI-assisted, data-driven personalized screening — expect future interest in digital health tools that integrate with organized hospital screening programs.

How they like to work

Strictly a participant — they have never coordinated an H2020 project, joining as a clinical partner providing patient data, cohorts, and validation capacity. They work in large consortia (129 unique partners across 8 projects), which is typical for major clinical centers embedded in multi-country health studies. This means they are experienced team players comfortable with complex governance structures, but you should not expect them to lead project management or administrative coordination.

Extensive European network spanning 129 unique partners across 20 countries, built through large-scale health research consortia. Their connections are strongest in Western and increasingly Eastern Europe, reflecting the EU-TOPIA expansion to Eastern European screening programs.

What sets them apart

As a major Italian university hospital, they offer something most research institutes cannot: direct access to large, diverse patient populations within an operational healthcare system. Their dual expertise in cancer screening programs and liver disease gives them an unusual cross-disease breadth for a clinical partner. For consortium builders, they bring the credibility and data infrastructure of a top-tier public hospital, which strengthens clinical validation claims in any health-focused proposal.

Highlights from their portfolio

• MyPeBS
  Largest single grant (EUR 703K) — an ambitious international randomized study comparing personalized risk-based breast cancer screening to standard approaches, running until 2027.
• RISCC
  Represents their strategic pivot to digital health — combines cervical cancer screening with predictive modelling, health-economic analysis, and digital applications.
• LIVERHOPE
  A focused therapeutic trial testing a specific drug combination (simvastatin + rifaximin) for decompensated cirrhosis — their most clinically concrete project.